{
    "organizations": [],
    "uuid": "ab60c7dd9c012af3d0efb4c8cc46632610e28f88",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-galectin-therapeutics-q1-loss-per/brief-galectin-therapeutics-q1-loss-per-share-0-12-idUSASC0A1TP",
    "ord_in_thread": 0,
    "title": "BRIEF-Galectin Therapeutics Q1 Loss Per Share $0.12",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 11 (Reuters) - Galectin Therapeutics Inc:\n* GALECTIN THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE\n* Q1 LOSS PER SHARE $0.12 * GALECTIN THERAPEUTICS - HAS ENOUGH CASH TO FUND CURRENTLY PLANNED OPERATIONS, RESEARCH & DEVELOPMENT ACTIVITIES THROUGH AT LEAST MARCH 31, 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-12T04:16:00.000+03:00",
    "crawled": "2018-05-12T17:25:28.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "galectin",
        "therapeutic",
        "inc",
        "galectin",
        "therapeutic",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "provides",
        "business",
        "update",
        "q1",
        "loss",
        "per",
        "share",
        "galectin",
        "therapeutic",
        "enough",
        "cash",
        "fund",
        "currently",
        "planned",
        "operation",
        "research",
        "development",
        "activity",
        "least",
        "march",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}